Leading Indian pharmaceutical research company Aurobindo Pharma is planning to expand its Active Pharmaceuticals Ingredients (API) manufacturing capacity, providing direct job opportunity to 300 people and indirect employment to about 600 people, a media report said.
The company will invest Rs 250 crore to increase API manufacturing capacity of its plant in Ranasthalam mandal in Srikakulam district, Andhra Pradesh, the Economic Times reported.
It is proposed to expand the API manufacturing capacity from the existing 583.31 TPM (Total Productive Maintenance) to 1518.3 TPM and captive power plant to 8.85MW by using steam from existing boilers in an existing area of 165 acres, according to the pre-feasibility report submitted to the Ministry of Environment and Forests.
The capital cost for expansion is Rs 250 crore towards de-bottlenecking, additional manufacturing blocks and facilities at the Ranasthalam mandal facility, the report added.
The project is envisaged to meet the demand supply gap in both domestic market and export market owing to the increasing demand of API.
The project expansion will also mean an increase in the total water requirement from 1588.6 KLD (kilo liters per day) to 4043 KLD. The water demand is to be met by ground water supply and from recycled water.